Empire analyst Cathy Reese initiated Insulet with a Sell rating and $15 price target on shares. The analyst believes Insulet's has several issues with its OmniPod System that will not be remedied by with planned upgrades. These issues include the pod can be knocked of the body, which has to be replaced by a new pod, the insulin in the pod that is knocked off cannot be recaptured so additional insulin is required,the monthly cost for an OmniPod System is typically more than its durable pump competitors despite a lower upfront cost, and the Centers for Medicare & Medicaid Services does not reimburse for the OmniPod's pod because it is classified as disposable. In addition, product innovation in the insulin pump market are intensifying, Reese adds.